Adagio Therapeutics to Submit an EUA Application to the U.S. FDA
Adagio Therapeutics, Inc. (Nasdaq: ADGI) today announced plans to engage with the U.S. Food and Drug Administration (FDA) to submit an Emergency Use Authorization (EUA) application for adintrevimab for both the prevention and treatment of COVID-19. Shares Surge Over 40%...